Avadel Pharmaceuticals plc (AVDL)
21.64
+0.01 (0.05%)
Inactive · Last trade price on Feb 11, 2026
Avadel Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 248.52 | 169.12 | 27.96 | - | - | 22.33 | |
Revenue Growth | 79.88% | 504.79% | - | - | - | -62.28% |
Cost of Revenue | 12.64 | 15.28 | 0.85 | - | - | 5.74 |
Gross Profit | 235.88 | 153.84 | 27.12 | - | - | 16.59 |
Selling, General & Admin | 196.96 | 181.04 | 151.71 | 74.52 | 68.5 | 32.41 |
Research & Development | 39.89 | 15.2 | 13.26 | 20.7 | 17.1 | 20.44 |
Amortization of Goodwill & Intangibles | - | - | - | - | - | 0.41 |
Operating Expenses | 236.86 | 196.24 | 164.97 | 95.22 | 85.6 | 53.25 |
Operating Income | -0.98 | -42.4 | -137.85 | -95.22 | -85.6 | -36.66 |
Interest Expense | -9.71 | -10.83 | -9.89 | -12.34 | -9.94 | -12.99 |
Interest & Investment Income | 1.33 | 2.53 | - | - | 2.44 | 0.41 |
Other Non Operating Income (Expenses) | - | - | 1.89 | 1.22 | - | - |
EBT Excluding Unusual Items | -9.35 | -50.7 | -145.85 | -106.34 | -93.1 | -49.25 |
Merger & Restructuring Charges | - | - | - | -3.35 | 0.05 | 0.04 |
Gain (Loss) on Sale of Investments | 0.6 | 1.63 | -1.8 | -1.75 | -0.1 | -0.44 |
Gain (Loss) on Sale of Assets | - | - | - | - | - | 45.76 |
Legal Settlements | - | - | - | - | - | -0.8 |
Other Unusual Items | 5.5 | - | -13.13 | - | - | -0.4 |
Pretax Income | -3.26 | -49.08 | -160.78 | -111.44 | -93.15 | -5.08 |
Income Tax Expense | -2.98 | -0.25 | -0.5 | 26.03 | -15.82 | -12.11 |
Earnings From Continuing Operations | -0.28 | -48.83 | -160.28 | -137.46 | -77.33 | 7.03 |
Net Income | -0.28 | -48.83 | -160.28 | -137.46 | -77.33 | 7.03 |
Net Income to Common | -0.28 | -48.83 | -160.28 | -137.46 | -77.33 | 7.03 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 97 | 95 | 80 | 60 | 59 | 53 |
Shares Outstanding (Diluted) | 97 | 95 | 80 | 60 | 59 | 55 |
Shares Change | 3.42% | 18.67% | 33.41% | 2.66% | 6.54% | 46.89% |
EPS (Basic) | -0.00 | -0.51 | -2.00 | -2.29 | -1.32 | 0.13 |
EPS (Diluted) | -0.00 | -0.51 | -2.00 | -2.29 | -1.32 | 0.13 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Free Cash Flow | 34.35 | -46.91 | -128.51 | -71.02 | -77.34 | -48.83 |
Free Cash Flow Per Share | 0.35 | -0.49 | -1.60 | -1.18 | -1.32 | -0.89 |
Gross Margin | 94.91% | 90.97% | 96.97% | - | - | 74.29% |
Operating Margin | -0.39% | -25.07% | -492.97% | - | - | -164.15% |
Profit Margin | -0.11% | -28.88% | -573.17% | - | - | 31.47% |
Free Cash Flow Margin | 13.82% | -27.74% | -459.57% | - | - | -218.64% |
EBITDA | 2.7 | -39.72 | -136.08 | -93.72 | -84.78 | -34.97 |
EBITDA Margin | 1.09% | -23.48% | - | - | - | -156.58% |
D&A For EBITDA | 3.68 | 2.68 | 1.77 | 1.49 | 0.82 | 1.69 |
EBIT | -0.98 | -42.4 | -137.85 | -95.22 | -85.6 | -36.66 |
EBIT Margin | -0.39% | -25.07% | - | - | - | -164.15% |
Advertising Expenses | - | - | - | - | - | 0.31 |